Cargando…
The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients
There are various melanoma treatment strategies that are based on immunological responses, among which immune checkpoint inhibitors (ICI) are relatively novel form. Nowadays, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death-1 (PD-1) antibodies represent a standard...
Autores principales: | Tomela, Katarzyna, Pietrzak, Bernadeta, Schmidt, Marcin, Mackiewicz, Andrzej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600343/ https://www.ncbi.nlm.nih.gov/pubmed/32992737 http://dx.doi.org/10.3390/life10100219 |
Ejemplares similares
-
A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition
por: Pietrzak, Bernadeta, et al.
Publicado: (2022) -
Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
por: Tomela, Katarzyna, et al.
Publicado: (2023) -
Secretory IgA in Intestinal Mucosal Secretions as an Adaptive Barrier against Microbial Cells
por: Pietrzak, Bernadeta, et al.
Publicado: (2020) -
The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018) -
Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)